Evidence map›Paper›PMID 34111256›Full record

ArticleTranslational vision science & technology2021

Optogenetic Modulation of Intraocular Pressure in a Glucocorticoid-Induced Ocular Hypertension Mouse Model.

Tia J Kowal, Philipp P Prosseda, Ke Ning, Biao Wang, Jorge Alvarado, Brent E Sendayen, Sayena Jabbehdari, W Daniel Stamer, Yang Hu, Yang Sun

Open access · goldAbstract read
In one paragraph

Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Primary Cilia of Astrocytes in the Retina in Development and Disease.Investigative ophthalmology & visual science · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tia J KowalDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Philipp P ProssedaDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Ke NingDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Biao WangDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Jorge AlvaradoDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Brent E SendayenDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Sayena JabbehdariDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
W Daniel StamerDuke Eye Center, Department of Ophthalmology, Duke University, Durham, NC, USA.
Yang HuDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Yang SunDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Stanford University · USDuke University · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
Elucidating Neuron-Intrinsic Molecular Mechanisms of Optic Nerve RegenerationR01EY024932 · NEI · TEMPLE UNIV OF THE COMMONWEALTH · PI Yang Hu · 2015 to 2026
$4.8M
Neuroprotection by Modulating ER Stress in GlaucomaR01EY023295 · NEI · TEMPLE UNIV OF THE COMMONWEALTH · PI HU, YANG · 2013 to 2022
$3.8M
The role of primary cilia in glaucoma pathogenesisR01EY025295 · NEI · STANFORD UNIVERSITY · PI Yang Sun · 2016 to 2026
$3.5M
Stanford Vision Training ProgramT32EY027816 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2018 to 2026
$2.0M
Developing Novel Neuroprotective Strategies for EAE/Optic NeuritisR01EY028106 · NEI · STANFORD UNIVERSITY · PI HU, YANG · 2018 to 2021
$1.9M
Phosphoinositide signaling in glaucoma: rescue strategies for Lowe syndromeR01EY032159 · NEI · STANFORD UNIVERSITY · PI SUN, YANG · 2021 to 2024
$1.6M
Development and Characterization of Silicone Oil-Induced Reversible Ocular Hypertension Glaucoma Model R21EY031063 · NEI · STANFORD UNIVERSITY · PI HU, YANG · 2019 to 2019
$324k
Transcriptional activation for rare disease rescueF32EY032775 · NEI · STANFORD UNIVERSITY · PI KOWAL, TIA J · 2021 to 2022
$101k
NEI NIH HHS F32 EY032775NEI NIH HHS P30 EY026877NEI NIH HHS R01 EY023295NEI NIH HHS R01 EY024932NEI NIH HHS R01 EY025295NEI NIH HHS R01 EY028106NEI NIH HHS R01 EY032159NEI NIH HHS R21 EY031063NEI NIH HHS T32 EY027816
6 · The paper itself

Abstract

Purpose: Steroid-induced glaucoma is a common form of secondary open angle glaucoma characterized by ocular hypertension (elevated intraocular pressure [IOP]) in response to prolonged glucocorticoid exposure. Elevated IOP occurs with increased outflow resistance and altered trabecular meshwork (TM) function. Recently, we used an optogenetic approach in TM to regulate the 5-phosphatase, OCRL, which contributes to regulating PI(4,5)P2 levels. Here, we applied this system with the aim of reversing compromised outflow function in a steroid-induced ocular hypertension mouse model. Methods: Elevated IOP was induced by chronic subconjunctival dexamethasone injections in wild-type C57Bl/6j mice. AAV2 viruses containing optogenetic modules of cryptochrome 2 (Cry2)-OCRL-5ptase and CIBN-GFP were injected into the anterior chamber. Four weeks after viral expression and dexamethasone exposure, IOP was measured by tonometer and outflow facility was measured by perfusion apparatus. Human TM cells were treated with dexamethasone, stimulated by light and treated with rhodamine-phalloidin to analyze actin structure. Results: Dexamethasone treatment elevated IOP and decreased outflow facility in wild-type mice. Optogenetic constructs were expressed in the TM of mouse eyes. Light stimulation caused CRY2-OCRL-5ptase to translocate to plasma membrane (CIBN-CAAX-GFP) and cilia (CIBN-SSTR3-GFP) in TM cells, which rescued the IOP and outflow facility. In addition, aberrant actin structures formed by dexamethasone treatment were reduced by optogenetic stimulation in human TM cells in culture. Conclusions: Subcellular targeting of inositol phosphatases to remove PIP2 represents a promising strategy to reverse defective TM function in steroid-induced ocular hypertension. Translational Relevance: Targeted modulation of OCRL may be used to decrease steroid-induced elevated IOP.

Indexed as

GlaucomaGlaucoma, Open-AngleOcular HypertensionAnimalsGlucocorticoidsIntraocular PressureMiceMice, Inbred C57BLOptogeneticsGlucocorticoids

Identifiers

PMID34111256
PMCPMC8107493
OpenAlexW3161907529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.